Recent news on Mecamylamine

IntelGenx Technologies Corp. and Cary Pharmaceuticals Inc. Today ...  -  May 3, 2007
SYS-CON Media,The plasma profiles of Bupropion and Mecamylamine after administration to 7 of a total of 10 subjects demonstrate that the once-daily formulation meets the

Targacept Reports First Quarter 2007 Financial Results  -  May 9, 2007
PR-Inside.com (Pressemitteilung),Conducted additional preclinical testing and pharmaceutical development of TC-5214, an enantiomer of mecamylamine hydrochloride that the company expects

CoMentis initiates phase 2 trial of topical AMD drug  -  Apr 18, 2007
OSN SuperSite (subscription),SOUTH SAN FRANCISCO — CoMentis Inc. has initiated a phase 2 clinical study evaluating a topical ophthalmic formulation of mecamylamine for treating

CoMentis Initiates Phase II Clinical Trial for AMD Eye Drop Therapy  -  Apr 10, 2007
PipelineReview.com (press release),A proprietary ophthalmic formulation of mecamylamine, ATG3 is an antagonist of the nicotinic acetylcholine (nACh) receptor pathway that mediates

UK smaller company results for 2 weeks to April 20  -  Apr 5, 2007
Hemscott,In February, AGI also announced that its diarrhoea drug (mecamylamine) and dyspepsia drug (arbaclofen) did not meet their primary targets in pilot phase II

OUTLOOK - UK smaller company results for  -  Mar 30, 2007
Hemscott,In February, AGI also announced that its diarrhoea drug (mecamylamine) and NHNT;MRX;BAY;HYDG;CTR;GBR,MED,ENG,LEI,SVS,STK,ERN/OUTLOOK - UK smaller company

QuitPak enters pilot study  -  Feb 13, 2007
In-PharmaTechnologist.com,The new therapy, which combines bupropion and mecamylamine, is undergoing trials to determine the suitability of IntelGenx' extended release formulation for

Targacept Reports Fourth Quarter and 2006 Financial Results  -  Feb 22, 2007
MSN MoneyAnnounced positive top line results of the Phase II clinical trial of mecamylamine hydrochloride as an augmentation therapy to citalopram hydrobromide,

AGI says diarrhoea, dyspepsia drugs miss main goals in pilot ...  -  Feb 1, 2007
Hemscott,Patients treated with the mecamylamine product for diarrhoea failed to show a statistically significant difference from placebo in the primary and secondary

Targacept to Expand Facilities at Piedmont Triad Research Park  -  Feb 1, 2007
Drug Newswire (press release),In November 2006, Targacept reported positive top line results from a Phase II clinical trial of TRIDMAC(TM), which evaluated mecamylamine hydrochloride as

Athenagen's Eye Drop Therapy for AMD Is Safe and Well Tolerated in ...  -  Jan 31, 2007
Genetic Engineering News (press release),ATG3, a proprietary ophthalmic formulation of mecamylamine, is an antagonist of the nicotinic acetylcholine (nACh) receptor pathway that mediates

Targacept Initiates Phase I Clinical Trial of TC-2216  -  Jan 9, 2007
Drug Newswire (press release),Mecamylamine hydrochloride binds non-selectively to various NNR subtypes, but there is a body of scientific evidence that suggests that its anti-depressant

Promising treatments target depression, aim at body's response to ...  -  Dec 14, 2006
Pittsburgh Post Gazette,Targacept Inc. just finished a midstage study showing that mecamylamine, an old blood-pressure drug it got from Merck, acts as an antidepressant by working

Targacept Releases Antidepressant Data  09 Nov 2006
Phase II clinical trial, patients who did not respond to Forest Laboratories (nyse: FRX - news - people )' Celexa were given mecamylamine hydrochloride along ... -Forbes, AGI Therapeutics sees continued progress in  Sep 7, 2006
...showing statistically significant superiority versus placebo and completed enrolment and treatment in a Phase II trial in 82 patients for mecamylamine (AGI-004 ... -Hemscott

Athenagen Initiates Clinical Development Of Its Anti-Angiogenic ...  Aug 22, 2006
ATG003 is a proprietary topical formulation of mecamylamine that has shown efficacy in animal models and is a possible alternative to current therapies for AMD ... -Medical News Today

Athenagen Initiates Clinical Development of its Anti-angiogenic ...  Aug 22, 2006
ATG003 is a proprietary topical formulation of mecamylamine that has shown efficacy in animal models and is a possible alternative to current therapies for AMD ... -PipelineReview.com

Athenagen begins testing eye drop therapy in humans  Aug 22, 2006
ATG003 is a proprietary topical formulation of mecamylamine that has shown efficacy in animal models and is a possible alternative to current therapies for age ... -Pharmaceutical Business Review

Targacept Reports Second Quarter 2006 Financial Results  Aug 9, 2006
Completed the dosing phase of Targacept's ongoing Phase II trial of mecamylamine hydrochloride as an add-on therapy for depression in August. ... -PR Newswire

Targacept to Report Second Quarter 2006 Financial Results on ...  Aug 2, 2006
Targacept has a marketed product, Inversine(R) (mecamylamine hydrochloride), product candidates in development for Alzheimer's disease and cognitive deficits ... -PR Newswire

Athenagen Gains New AD Platform Via Zapaq Merger  Jul 11, 2006
The company, founded in 2004, also expects to move ATG003 into clinical trials this summer as an eye drop formulation of mecamylamine to treat age-related ... -BioWorld Online

Athenagen and Zapaq to Merge  Jul 10, 2006
ATG003 is a proprietary topical (eye drop) formulation of mecamylamine that has shown efficacy in animal models and presents a possible alternative to current ... -Yahoo! News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional